Perella's Tokum Healthcare Fund Goes UCITS

Aug 19 2011 | 4:46am ET

Perella Weinberg Partners has launched a UCITS III-compliant version of the healthcare hedge fund it acquired last year.

Perella's Tokum fund invests across the healthcare industry, in biotechnology, pharmaceuticals, medical technology and other areas. The four-year-old fund is run by former Amaranth Advisors portfolio manager Emile Westergaard. Perella Weinberg hired Westergaard and took over Tokum's funds early last year.

The MS Perella Weinberg Partners Tokum Long/Short Healthcare UCITS Fund debuted yesterday on Morgan Stanley's UCITS platform, FundLogic Alternatives.

The fund "will leverage our team's bottom-up fundamental research process to identify, within the healthcare industry’s rapidly evolving technological and regulatory frameworks, material levers impacting businesses positively or negatively over a two to four-year horizon," Westergaard said. "We strongly believe our unique portfolio construction matrix, which has been developed to take into account a multi-factored set of inputs guided by absolute return objectives, implied volatility targets and liquidity requirements, fits well within the UCITS framework.”


In Depth

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Lifestyle

Einhorns Busts At WSOP, Finishes In 173rd

Jul 15 2014 | 10:48am ET

Greenlight Capital founder David Einhorn’s World Series of Poker won’t end at...

Guest Contributor

Common Risk Parity Misperceptions

Jul 16 2014 | 11:02am ET

Over the past few years, risk parity has become a component of most investors’...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note